https://www.nasdaq.com/press-release/arvinas-and-pfizer-announce-protacr-protein-degrader-arv-471-continues-to-demonstrate
https://www.nasdaq.com/press-release/arvinas-and-pfizer-announce-updated-phase-1-dose-escalation-data-for-arv-471-to-be
https://www.nasdaq.com/press-release/arvinas-to-present-at-stifel-2021-virtual-healthcare-conference-2021-11-10
https://www.nasdaq.com/press-release/arvinas-reports-third-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arvinas-to-participate-in-upcoming-virtual-investor-conferences-2021-09-01
https://www.nasdaq.com/press-release/insilico-medicine-announces-an-ai-driven-protac-rd-collaboration-with-arvinas-2021-08
https://www.nasdaq.com/press-release/arvinas-reports-second-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arvinas-and-pfizer-announce-global-collaboration-to-develop-and-commercialize-protacr
https://www.nasdaq.com/press-release/arvinas-participates-in-groundbreaking-ceremony-for-new-space-within-downtown
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-42nd-annual-goldman-sachs-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-ubs-global-healthcare-virtual-conference-2021-05-20
https://www.nasdaq.com/press-release/arvinas-signs-lease-for-new-space-within-downtown-crossing-development-in-new-haven
https://www.nasdaq.com/press-release/arvinas-reports-first-quarter-2021-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arvinas-announces-upcoming-presentations-at-the-american-association-for-cancer
https://www.nasdaq.com/press-release/arvinas-to-participate-in-upcoming-virtual-investor-conferences-2021-03-10
https://www.nasdaq.com/press-release/arvinas-reports-fourth-quarter-and-full-year-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-guggenheim-healthcare-talks%3a-2021-oncology-day-2021-02-08
https://www.nasdaq.com/press-release/arvinas-inc.-announces-exercise-of-underwriters-option-to-purchase-additional-shares
https://www.nasdaq.com/press-release/arvinas-inc.-announces-pricing-of-%24400-million-public-offering-of-common-stock-2020
https://www.nasdaq.com/press-release/arvinas-inc.-announces-proposed-offering-of-common-stock-2020-12-14
https://www.nasdaq.com/press-release/arvinas-releases-interim-clinical-data-further-demonstrating-the-powerful-potential
https://www.nasdaq.com/press-release/arvinas-to-host-webcast-presentation-of-new-clinical-data-from-arv-471-and-arv-110
https://www.nasdaq.com/press-release/arvinas-to-participate-in-upcoming-virtual-investor-conferences-2020-11-25
https://www.nasdaq.com/press-release/arvinas-reports-third-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arvinas-announces-pipeline-programs-targeting-validated-and-classically-undruggable
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-3rd-annual-targeted-protein-degradation-summit-2020-10-06
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-citi-15th-annual-biopharma-virtual-conference-2020-09-04
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-2020-wedbush-pacgrow-virtual-healthcare-conference-2020-08
https://www.nasdaq.com/press-release/arvinas-reports-second-quarter-2020-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arvinas-appoints-wendy-dixon-ph.d.-to-its-board-of-directors-2020-06-29
https://www.nasdaq.com/press-release/arvinas-to-present-virtually-at-the-bmo-2020-prescriptions-for-success-healthcare
https://www.nasdaq.com/press-release/arvinas-appoints-linda-bain-to-its-board-of-directors-2020-06-11
https://www.nasdaq.com/press-release/arvinas-to-present-virtually-at-the-goldman-sachs-41st-annual-global-healthcare
https://www.nasdaq.com/press-release/arvinas-releases-updated-dose-escalation-data-from-clinical-trial-of-protacr-protein
https://www.nasdaq.com/press-release/arvinas-to-hold-virtual-2020-annual-meeting-of-stockholders-2020-05-20
https://www.nasdaq.com/press-release/arvinas-announces-updated-phase-1-data-demonstrating-clinical-activity-of-protacr
https://www.nasdaq.com/press-release/arvinas-reports-first-quarter-2020-financial-results-and-provides-a-corporate-update
https://www.nasdaq.com/press-release/arvinas-provides-update-on-business-continuity-related-to-the-impact-of-the-covid-19
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-american-society-of-clinical-oncology-annual-meeting-2020
https://www.nasdaq.com/press-release/arvinas-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/arvinas-to-present-at-the-31st-annual-piper-jaffray-healthcare-conference-2019-11-27
https://www.nasdaq.com/press-release/arvinas-appoints-laurie-smaldone-alsup-m.d.-to-board-of-directors-2019-11-21
https://www.nasdaq.com/press-release/arvinas-inc.-announces-pricing-of-public-offering-of-common-stock-2019-11-06
https://www.nasdaq.com/press-release/arvinas-inc.-announces-proposed-offering-of-common-stock-2019-11-06
https://www.nasdaq.com/press-release/arvinas-reports-third-quarter-2019-financial-results-and-provides-corporate-update
https://www.nasdaq.com/press-release/arvinas-presents-a-platform-update-including-initial-data-from-the-first-two-clinical
https://www.nasdaq.com/press-release/arvinas-to-present-initial-data-from-ongoing-clinical-trials-and-a-pipeline-update-at
https://www.nasdaq.com/press-release/arvinas-strengthens-scientific-advisory-board-with-leaders-in-oncology-and
